UMB Bank, N.A. v. Bristol-Myers Squibb Company

District Court, S.D. New York·Decided August 9, 2022·No. 1:21-cv-04897·Unknown

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK ---------------------------------------- x : UMB BANK, N.A., solely in its capacity : as Trustee under the Contingent Value : Rights Agreement by and between : Bristol-Myers Squibb Company and : Equiniti Trust Company, dated as of : November 20, 2019, : Case No. 1:21-cv-04897 (JMF) : Plaintiff, : : v. : : : BRISTOL-MYERS SQUIBB COMPANY, : Defendant. : : ---------------------------------------- x STIPULATION AND [PROPOSED] ORDER GOVERNING CONFIDENTIALITY OF DISCOVERY MATERIALS AND PRESERVATION OF PRIVILEGE Subject to the approval of the Court, pursuant to Rule 26(c) of the Federal Rules of Civil Procedure and Rule 502(d) of the Federal Rules of Evidence, plaintiff UMB Bank, N.A., in its capacity as trustee (the “Trustee”) under the Contingent Value Rights Agreement dated as of November 20, 2019 (the “CVR Agreement”), and defendant Bristol-Myers Squibb Company (“BMS”) (together, the “Parties” and each a “Party”), by their undersigned counsel, stipulate and agree as follows: 1. PURPOSE 1.1 Disclosure and discovery activity in this Action are likely to involve production of confidential, proprietary, or private information for which special protection from public disclosure and from use for any purpose other than prosecuting, defending, or attempting to settle this Action may be warranted. Accordingly, the Parties hereby stipulate to and petition the United States District Court for the Southern District of New York (the “Court”) to enter an Order approving this Stipulation (the “Order”). 1.2 The purpose of this Order is to facilitate the production of discovery material and the prompt resolution of disputes over confidentiality and privilege, to protect material to be kept confidential and/or privileged, and to ensure that protection is afforded to material entitled to such

treatment, pursuant to the Court’s inherent authority, its authority under Fed. R. Civ. P. 16 and 26 and Fed. R. Evid. 502(d), the judicial opinions interpreting such Rules, and any other applicable law. 1.3 This Order shall be binding on the Parties and their counsel in this Action and on any other persons or entities who become bound by this Order by signifying their assent through execution of the “Acknowledgment and Agreement to Be Bound,” attached as Exhibit A hereto (an “Acknowledgement”). The Party seeking to share Confidential or Highly Confidential materials with a third-party shall be responsible for having the third-party execute an Acknowledgement and for maintaining a copy of the executed Acknowledgement on file. A

Designating Party may request a copy of an executed Acknowledgement only if that party has a reasonable, good faith belief that Protected Material has been improperly used or disclosed. 2. DEFINITIONS The following definitions apply for purposes of this Order: 2.1 Action: This lawsuit. 2.2 Attorney’s Eyes Only Information: Discovery Material which the Producing Party believes in good faith contains or reflects extremely sensitive proprietary information, trade secrets or competitive or commercial information for which disclosure to another party or an employee or officer of such other party would create a substantial risk of serious harm that could not be avoided by less restrictive means. 2.3 Challenging Party: A Party that challenges the designation of information or items under this Order. 2.4 Confidential Information: Discovery Material (regardless of how it is generated,

stored or maintained) or tangible things that the Producing Party reasonably and in good faith believes constitutes and reveals confidential trade secrets, proprietary business information, non- public personal or client information concerning individuals or other entities (including but not limited to names, telephone numbers, email addresses, mailing addresses, credit and banking information), previously nondisclosed financial information; previously nondisclosed business plans, product development information, forecasts, projections, or marketing plans; previously nondisclosed materials constituting or containing confidential research and development, technical, sales, marketing, personnel, customer, vendor or other commercial information; or other information that the Producing Party reasonably believes would result in competitive, commercial

or financial harm to the Producing Party or its personnel or customers. 2.5 Counsel: Outside Counsel of Record and In-House Counsel (as well as their employees and support staff). 2.6 Designating Party: A Party or Non-Party that designates documents, information, or items that it produces in disclosures or in responses to discovery as “CONFIDENTIAL,” “HIGHLY CONFIDENTIAL,” or “ATTORNEY’S EYES ONLY.” 2.7 Disclosed Privileged Material: All Discovery Material that a Party or Non-Party discloses that it thereafter claims to be Privileged Material. 2.8 Disclosing Party: A Party or Non-Party that discloses Disclosed Privileged Material in this Action. 2.9 Discovery Material: All items or information, regardless of the medium or manner in which it is generated, stored, or maintained (including, among other things, testimony, transcripts, answers to interrogatories, documents, responses to requests for admissions, tangible

things, and informal exchanges of information), that are produced or generated in connection with any discovery in this Action, whether formally or informally. 2.10 Expert: A person retained by a Party or its Counsel to serve as an expert witness or consultant or technical advisor in this Action (as well as his or her employees and support staff). 2.11 Private Data: Any information that a Party believes in good faith to be subject to federal, state, or foreign data protection laws or other privacy obligations, including, without limitation, The Health Insurance Portability and Accountability Act and the regulations thereunder (“HIPAA”), 45 C.F.R. Part 160 and Subparts A and E of Part 164 (medical information); the Genetic Information Non-Discrimination Act of 2008 (“GINA”) (biometric information);

Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 on the Protection of Natural Persons with Regard to the Processing of Personal Data and on the Free Movement of Such Data (“General Data Protection Regulation” or “GDPR”); Data Protection Act 2018 (c. 12) (United Kingdom personal information); Person Information Protection and Electronic Documents Act (“PIPEDA”), S.C. 200, c. 5 (Canada personal information); The Federal Law on Protection of Personal Data held by Private Persons (published July 5, 2010) (Mexico personal information); The Act on the Protection of Personal Information (Law No. 57 of 2003) (APPI) (Japan personal information); and The Security Technology Personal Information Security Specification GB/T 35273-2017 (“China Data Protection Law”). Private Data constitutes Highly Confidential Information under the terms of this Order. 2.12 Highly Confidential Information: Discovery Material that: (a) is foreign Private Data; or (b) meets the definition of “Confidential Information” and which the Designating Party reasonably believes to be (i) non-public information reflecting product design or development,

Free access — add to your briefcase to read the full text and ask questions with AI

UMB Bank, N.A. v. Bristol-Myers Squibb Company, (S.D.N.Y. 2022).

UMB Bank, N.A. v. Bristol-Myers Squibb Company (UMB Bank, N.A. v. Bristol-Myers Squibb Company) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.